21 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
). To the Company’s knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley … , LLC during the Lock-Up Period.
4.19 Research Independence. The Company acknowledges that each Underwriter’s research analysts and research
8-K
EX-10.1
CGTX
Cognition Therapeutics Inc
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act
S-3
EX-1.2
a40jeyd11acxnh8
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
i8y2z8vanij8jqp
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
nuak1pyywoo
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
otlyr0j5uf3j7jejg
20 Oct 22
Draft registration statement
12:00am
DEF 14A
y66u6sdkb
25 Apr 22
Definitive proxy
5:28pm
10-K
4k3x091bf267
30 Mar 22
Annual report
7:40am
10-Q
tnmo8kk n926ees6cmq
17 Nov 21
Quarterly report
5:15pm
424B4
tepofneomjgjxajcu 8k
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
xlyud1zfk
19 Jul 21
IPO registration
7:02am
DRS/A
2eh03cv 507pdm
23 Jun 21
Draft registration statement (amended)
12:00am